News

Explore Moderna's growth potential with FDA-approved respiratory vaccines, strong cash reserves, and a robust pipeline.
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...
The FDA has approved Moderna’s next-generation COVID-19 vaccine for people older than 65. REUTERS “The FDA approval of our third product, mNEXSPIKE, ...
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...